Marginal zone lymphoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 3, 2006, Pages 311-318

  Shaye, Omid S ^a,b   Levine, Alexandra M ^a,b  

^a University of Southern California ^*

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

MALT lymphoma; Marginal zone lymphoma; Nodal marginal zone lymphoma; Splenic marginal zone lymphoma

Indexed keywords

ALKYLATING AGENT; ALPHA2B INTERFERON; AMOXICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BISMUTH SALICYLATE; BORTEZOMIB; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; FLUDARABINE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIBAVIRIN; RITUXIMAB; TETRACYCLINE;

B LYMPHOCYTE; BORRELIA BURGDORFERI; CAMPYLOBACTER JEJUNI; CHLAMYDOPHILA PSITTACI; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; EXTRANODAL MARGINAL ZONE LYMPHOMA; GASTRIC MARGINAL ZONE LYMPHOMA; GASTRITIS; HELICOBACTER PYLORI; HEPATITIS C; HUMAN; LYMPHOID TISSUE; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; PATHOGENESIS; REVIEW; SIALOADENITIS; SJOEGREN SYNDROME; SMALL INTESTINE; SOMATIC HYPERMUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; STOMACH LYMPHOMA; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE; HELICOBACTER INFECTION; LYMPHOMA; MICROBIOLOGY; SPLEEN TUMOR; STOMACH TUMOR;

CHRONIC DISEASE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; SPLENIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 33645913238     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0026     Document Type: Review

References (73)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001:351.
3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
4. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer 1983;52:1410-1416.
5. Jonsson V, Wiik A, Hou-Jensen K, et al. Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders. J Intern Med 1999;245:277-286.
6. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid tissue lymphoma of the stomach. N Engl J Med 1998;338:804-810.
7. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR el al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1157-1176.
8. Doglioni C, Wotherspoon AC, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992;339:834-835.
9. Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to Campylobacter pylori. Scand J Oastroenterol 1998(suppl);142:44-49.
10. Qin Y, Greiner A, Trunk MJ, et al. Somatic hypermutation in low-grade mucosa-associated lymphoid tissue-type B-cell lymphoma. Blood 1995;86:3528-3534.
11. Wotherspoon AC, Doglioni C, Isaacson PG, et al. Regression of primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet 1993;342:575-577.
12. Chan JK. Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. Semin Diagn Pathol 1996;13:260-296.
13. Thiede C, Wundisch T, Alpen B, et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001;19:1600-1609.
14. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H prlori in gastric MALT lymphoma. Blood 2003;102:1012-1018.
15. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004;18:1722-1726.
16. Inagaki H, Nakamura T, Li C, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004;28:1560-1567.
17. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061-5066.
18. Ye H, Dogan A, Karran L, et al. BCL10 expresion in normal and neoplastic tissue: nuclear localization in MALT lymphoma. Am J Pathol 2000;157:1147-1154.
19. Farnha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:6370-6378.
20. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct genetic pathways. Blood 2002;99:3-9.
21. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397-400.
22. Steinbach G, Ford R, Globet G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999;131:88-95.
23. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-769.
24. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection: MALT Lymphoma Study Group. Lancet 1995;345:1591-1594.
25. Mogner A, Miehlke S, Fishbach S, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001;19:2041-2048.
26. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1999;131:88-95.
27. Liu H, Ye H, Ruskone-Fourmestraux A, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to Hpylori eradication. Gastroenterology 2002;122:1286-1294.
28. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-1921.
29. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-4164.
30. de Mascarel A, Ruskone-Fourmestraux A, Vavergne-Slove A, et al. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch 2005;446:219-224.
31. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877.
32. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gatric marginal zone NHL resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983.
33. O'Conner OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
34. Alpha-chain disease and related small intestinal lymphoma: a memorandum. Bull World Health Organ 1976,54:615-624.
35. Isaacson PG. Gastrointestinal lymphoma. Hum Pathol 1994;25:1020-1029.
36. Ramot B, Shahin N, Bubis JJ. Malabsorption syndrome in lymphoma of small intestine: a study of 13 cases. Isr Med J 1965;47:221-226.
37. Rambaud JC, Halphen M, Galian A, Tsapis A. Immunoproliferative small intestinal disease (IPSID): relationships with alpha-chain disease and "Mediterranean" lymphomas. Springer Semin Immunopathol 1990;12:239-250.
38. Khojasteh A, Haghighi P. Immunoproliferative small intestinal disease: portrait of a potentially preventable cancer from the Third World. Am J Med 1990;89:483-490.
39. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-248.
40. Ben-Ayed F, Halphen M, Najjar T, et al. Treatment of alpha chain disease: results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer 1989;63:1251-1256.
41. Akbulut H, Soykan I, Yakaryilmaz F, et al. Five-year results of the treatment of 23 patients with Immunoproliferative small intestinal disease: a Turkish experience. Cancer 1997;80:8-14.
42. Garbe C, Stein H, Dienemann D, et al. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991;24:584-590.
43. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997;24:457-461.
44. Roggero E, Zucca E, Mainetii C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263-268.
45. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-594.
46. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005;23:5067-5073.
47. Isaacson PG, Matutues C, Burke M et al. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994;84:3828-3834.
48. Chacon JI, Mollefo M, Munoz E, et al. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648-1654.
49. Troussard X, Valenci F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731-736.
50. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950-1956.
51. Audouin J, Le Tourneau A, Molina T, et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003;122:404-412.
52. Hernandez JM, Garcia JL, Gutierrez NC, et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol 2001;158:1843-1850
53. Rosenwald A, Ott G, Stilgenbauer S, et al. Exclusive detection of the t(11:18)(q21;q21) in extra-nodal marginal zone B cell lymphomas (MZBK) of MALT type in contrast to other MZBL and extra-nodal large B cell lymphomas. Am J Pathol 1999;155:1817-1821.
54. Sanchez-Izquierdo D, Buchonnet G, Siebert R, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkins lymphoma. Blood 2003;101:4539-4546.
55. Sole F, Salido M, Espinet B, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 2001;86:71-77.
56. Gruska-Westwood AM, Matutes E, Coignet LF, et al. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol 1999;104:600-604.
57. Oscier DG, Gardiner A, Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet Cytogenet 1996;92:24-27.
58. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299-1304.
59. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003;102:996-999.
60. Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005;105:74-76.
61. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468-473.
62. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999;36:148-154.
63. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginalzone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95-103.
64. Mulligan SP, Matutes E, Dearden C, et al. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206-209.
65. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1995;99:158-161.
66. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000;14:573-575.
67. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br J Haematol 1998;100:609.
68. Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000;40:113-117.
69. Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4:250-252.
70. Thomas D, O'Brian S, Cortes J, et al. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphoma (MZL) with single agent Rituximab [abstract]. Blood 2001;98:134a.
71. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types: nNon-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999;17:2486-2492.
72. Sheibani K, Burke JS, Swartz WG, et al. Monocytoid B-cell lymphoma: clinicopathologic study of 21 cases of a unique type of low-grade lymphoma. Cancer 1988;62:1531-1538.
73. Koh LP, Lim LC, Thng CH. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 2000;17:225-228.